Use of cholesterol‐lowering medications in relation to risk of primary liver cancer in the Clinical Practice Research Datalink
Open Access
Abstract
Background: Although the relation between statin use and liver cancer risk has been extensively examined, few studies have examined other cholesterol‐lowering medications in relation to liver cancer risk. The authors examined five classes of nonstatin medications and liver cancer risk.Methods: A nested case–control including 3719 cases and 14,876 matched controls was conducted within the Clinical Practice Research Datalink. Additional matches on type 2 diabetes and chronic liver disease were also implemented. The medications examined included cholesterol absorption inhibitors, bile acid sequestrants, fibrates, niacin, and omega‐3 fatty acids. Conditional logistic regression estimated odds ratios and 95% confidence intervals.Results: Cholesterol absorption inhibitor use was associated with reduced liver cancer risk in the overall analysis (odds ratio, 0.69; 95% confidence interval, 0.50–0.96) and in analyses based on type 2 diabetes and chronic liver disease status. Although bile acid sequestrant use was associated with increased liver cancer risk in the overall analysis (odds ratio, 5.31; 95% confidence interval, 3.53–7.97), the results of the analyses based on type 2 diabetes and chronic liver disease status were inconsistent. [Correction added on 19 August 2024, after first online publication: In the preceding sentence, the value ‘3.534’ has been changed to ‘3.54’.]. No associations were observed for the other medications.Conclusions: Cholesterol absorption inhibitors may be associated with reduced liver cancer risk. Whether bile acid sequestrant use was associated with increased risk was only partially supported in the current study.Keywords
This publication has 49 references indexed in Scilit:
- Epidemiology of Hepatocellular CarcinomaHepatology, 2020
- Inverse Association of Fibrates and Liver Cancer: A Population‐Based Case‐Control Study in TaiwanThe Journal of Clinical Pharmacology, 2019
- Projections of primary liver cancer to 2030 in 30 countries worldwideHepatology, 2017
- Associations of NSAID and paracetamol use with risk of primary liver cancer in the Clinical Practice Research DatalinkCancer Epidemiology, 2016
- Statin-Associated Side EffectsJACC, 2016
- Statin use and risk of hepatocellular carcinoma in a U.S. populationCancer Epidemiology, 2014
- Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.Hepatology, 2013
- Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanismsEuropean Journal of Cell Biology, 2011
- The effect of PPAR-α agonism on apolipoprotein metabolism in humansAtherosclerosis, 2010
- Inhibitors of Cholesterol Biosynthesis Increase Hepatic Low-Density Lipoprotein Receptor Protein DegradationArchives of Biochemistry and Biophysics, 1996